Liu Jun, Chen Feng-Hong, Qiu Shu-Qi, Yang Li-Tao, Zhang Huan-Ping, Liu Jiang-Qi, Geng Xiao-Rui, Yang Gui, Liu Zhi-Qiang, Li Jing, Liu Zhi-Gang, Li Hua-Bin, Yang Ping-Chang
Shenzhen Maternity & Child Health HospitalShenzhen 518052, China; The Center of Allergy & Immunology, School of Medicine, Shenzhen UniversityShenzhen 518060, China.
The Center of Allergy & Immunology, School of Medicine, Shenzhen UniversityShenzhen 518060, China; Allergy Center, Otorhinolaryngology Hospital, the First Affiliated Hospital of Sun Yat-sen UniversityGuangzhou 510080, China.
Am J Transl Res. 2016 Dec 15;8(12):5256-5270. eCollection 2016.
Immune regulatory system dysfunction plays a role in the pathogenesis of asthma. The therapeutic effect of allergic asthma is to be improved. The immune regulatory function of probiotics has been recognized. This study tests a hypothesis that (CB) enhances the effect of allergen specific immunotherapy (AIT) on asthma. In this study patients with allergic asthma were treated with AIT or/and CB for six months. The therapeutic effect and IgE production of the patients were observed. The results showed that administration with AIT alone alleviated the asthma symptoms; but the serum levels of interleukin (IL)-4, IL-5, IL-13 and specific IgE were not altered, which was markedly improved by the administration with CB plus AIT. Such effects were maintained only for two months in the patients treated with AIT alone; but maintained more than 12 months in those patients treated with both AIT and CB. CB facilitated AIT to induce IL-10 B cells (B10 cells) in asthma patients. AIT/CB therapy converted antigen specific B cells to antigen specific regulatory B cells. Butyrate modulated the gene transcription of IgE and IL-10 in the allergen specific B cells. In conclusion, administration of CB can enhance the therapeutic effect of AIT in the treatment of allergic asthma via facilitating generation of B10 cells.
免疫调节系统功能障碍在哮喘发病机制中起作用。变应性哮喘的治疗效果有待提高。益生菌的免疫调节功能已得到认可。本研究检验了一个假设，即[具体物质未明确，暂用(CB)表示]可增强变应原特异性免疫疗法(AIT)对哮喘的治疗效果。在本研究中，变应性哮喘患者接受AIT或/和CB治疗6个月。观察患者的治疗效果和IgE产生情况。结果显示，单独使用AIT可缓解哮喘症状；但白细胞介素(IL)-4、IL-5、IL-13和特异性IgE的血清水平未改变，而联合使用CB和AIT则有明显改善。单独接受AIT治疗的患者这种效果仅维持2个月；而接受AIT和CB联合治疗的患者则维持超过12个月。CB促进AIT诱导哮喘患者产生IL-10 B细胞(B10细胞)。AIT/CB疗法将抗原特异性B细胞转化为抗原特异性调节性B细胞。丁酸盐调节变应原特异性B细胞中IgE和IL-10的基因转录。总之，给予CB可通过促进B10细胞的产生来增强AIT治疗变应性哮喘的效果。
